CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results

CervoMed ( (CRVO) ) has shared an update.

On March 19, 2026, CervoMed reported new analyses from its Phase 2b RewinD-LB trial showing that DLB patients with lower plasma pTau181 levels, indicating absence of Alzheimer’s co-pathology and earlier-stage disease, experienced greater clinical benefit from neflamapimod. The data, to be presented March 21, 2026 at the AD/PD 2026 Conference, also demonstrate that a specific trough plasma concentration threshold is associated with clinical response, informing both patient enrichment and the 50mg TID dosing strategy for a planned Phase 3 trial.

Trial results showed that when patients switched from placebo to a reformulated neflamapimod capsule batch that reliably achieved target plasma levels, they had statistically significant and clinically meaningful slowing of disease progression, particularly in those with plasma pTau181 below 21 pg/mL. These findings strengthen CervoMed’s positioning in DLB by supporting a biomarker-driven Phase 3 design expected to enroll predominantly “pure” DLB patients without Alzheimer’s co-pathology, potentially increasing the likelihood of success and offering clearer value for future stakeholders if efficacy is confirmed.

The most recent analyst rating on (CRVO) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.

Spark’s Take on CRVO Stock

According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.

Score is held down primarily by weak financial performance (no revenue, worsening losses, and rising cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate updates provide some upside potential, but they do not yet offset near-term funding and momentum risks; valuation signals are limited due to negative earnings.

To see Spark’s full report on CRVO stock, click here.

More about CervoMed

CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing neflamapimod, an oral small-molecule inhibitor of p38α, for the treatment of dementia with Lewy bodies (DLB). The company targets neuroinflammation and synaptic dysfunction in DLB, aiming to address an area of high unmet medical need where no treatments are currently approved.

Average Trading Volume: 88,392

Technical Sentiment Signal: Sell

Current Market Cap: $39.26M

See more insights into CRVO stock on TipRanks’ Stock Analysis page.